Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Search for FDA Guidance Documents

Search for FDA Guidance Documents

                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents Home
          Regulatory Information
          Search for FDA Guidance Documents
          Direct Final Rule ProceduresSearch for FDA Guidance Documents GUIDANCE DOCUMENT
	Direct Final Rule Procedures
					Guidance for FDA and Industry
		
		November 1997


	 

    Final

	  
	  
	Share
    Post
    Linkedin

    Email
    PrintIssued by:
		    Guidance Issuing Office
          Office of the Commissioner, Office of Policy, Legislation, and International Affairs, Office of Policy


**U.S. Department of Health and Human Services
Food and Drug Administration
Office of Policy**

**November 21, 1997**

I. Summary

This guidance will explain when and how the Food and Drug Administration (FDA) will employ direct final rulemaking. FDA believes that direct final rulemaking will expedite the issuance of routine or otherwise noncontroversial rules.

II. FDA's Direct Final Rulemaking Procedures

This guidance adopts many aspects of the former Administrative Conference of the United States' (1964 to 1995) recommendations concerning direct final rulemaking. FDA may use the direct final rule process when the agency does not anticipate receiving any significant adverse comment, or when a rule may qualify for exemption from notice-and-comment rulemaking. FDA will publish in the notice of direct final rulemaking the full text of the rule and the statement of basis and purpose, including all the material that would be required in the preamble to a final rule. FDA will also publish a companion proposed rule in the same issue of the Federal Register. That proposed rule will serve the purpose of issuing a proposed rule under usual notice-and-comment procedures in the event the direct final rule is withdrawn because the agency receives any significant adverse comment.

FDA ordinarily will allow at least 75 days for comment on the direct final rule after it is published in the Federal Register. If the agency receives any significant adverse comment, the agency will publish a notice of significant adverse comment and withdraw the direct final rule within 30 days after the comment period ends. In that circumstance, any comments received will be considered comments on the proposed rule and will be considered in developing a final rule using the usual APA notice-and-comment procedures. If the agency receives no significant adverse comment during the specified comment period, the direct final rule will go into effect no later than 60 days after the comment period ends. The agency will publish a document confirming the effective date within 30 days after the comment period ends, which ordinarily will state that the direct final rule will go into effect 30 days after the confirmation notice is published. This means that a direct final rule that receives no significant adverse comment will go into effect no later than 135 days after its publication in the Federal Register.

FDA will adopt ACUS's definition of significant adverse comment. Thus, significant adverse comment is defined as one where the comment explains why the rule would be inappropriate, including challenges to the rule's underlying premise or approach, or would be ineffective or unacceptable without a change. In determining whether a significant adverse comment is sufficient to terminate a direct final rulemaking, FDA will consider whether the comment raises an issue serious enough to warrant a substantive response in a notice-and-comment process. FDA notes that comments that are frivolous, insubstantial, or outside the scope of the rule would not be considered adverse under this procedure. A comment recommending a rule change in addition to the rule would not be considered a significant adverse comment, unless the comment states why the rule would be ineffective without the additional change. In addition, if a significant adverse comment applies to part of a rule and that part can be severed from the remainder of the rule (e.g., where a rule deletes several unrelated regulations), FDA may adopt as final those parts of the rule that are not the subject of a significant adverse comment.

As discussed previously, FDA will only use direct final rulemaking procedures when the agency expects that there will be no significant adverse comment. For example, FDA will consider direct final rulemaking for minor, substantive changes to regulations; incorporation by reference of the latest edition of technical or industry standards; extensions of compliance dates, direct incorporations of mandates from new legislation; and other non controversial rules where FDA determines that use of direct final rulemaking is in the public interest and that the rule is unlikely to result in any significant adverse comment.

III. Significance of Guidance

The agency has adopted Good Guidance Practices (GGP's), which set forth the agency's policies and procedures for the development, issuance, and use of guidance documents (62 FR 8961, February 27, 1997). This guidance is issued as Level 1 guidance consistent with GGP's. The agency will not solicit public input prior to implementation because the guidance presents a less burdensome policy that is consistent with the public health. This guidance represents the agency's current thinking on direct final rules. It does not operate to create or confer any right sfor or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulation, or both.

IV. Request for Comments

Interested persons may, at any time, submit written comments on this guidance to the Dockets Management Branch (address above). Such comments will be considered when determining whether to amend the current guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy.


 
	Submit Comments
	   		  			  			Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
						If unable to submit comments online, please mail written comments to:
						Dockets Management
							Food and Drug Administration
							5630 Fishers Lane, Rm 1061
							Rockville, MD 20852
						All comments should be identified with the title of the guidance.

                                                                                  Content current as of:
      03/21/2018
         
                  
Regulated Product(s)
		 Animal & Veterinary
			  			     			  			     Biologics
			     			  			     Cosmetics
			     			  			     Dietary Supplements
			     			  			     Drugs
			     			  			     Food & Beverages
			     			  			     Medical Devices
			     			  			     Radiation-Emitting Products
			     			  			     Tobacco
			     			  						              
			
			
			
			
			
						  Food & Color AdditivesTopic(s)
			  Administrative / ProceduralSearch for FDA Guidance Documents

        Search for FDA Guidance Documents

          
                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop